Excellent response to cemiplimab and radiotherapy in advanced metastatic porocarcinoma

Documenti analoghi

• Secukinumab is effective in a patient on haemodialysis for end‐stage renal disease and severe hidradenitis suppurativa
  di: Nessr Abu Rached, et al.
  Pubblicazione: (2024)
• Immunotherapy versus targeted therapy for BRAF ‐mutant melanoma: A systematic review and meta‐analysis
  di: Priyanka C. Gaertner, et al.
  Pubblicazione: (2025)
• Real‐world multicentre observational study of effectiveness and toxicity in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
  di: L. Faoro, et al.
  Pubblicazione: (2024)
• YAP1‐NUTM1 fusions are infrequent in porocarcinomas arising in a cohort including immunocompromised patients
  di: Mark Eisner, et al.
  Pubblicazione: (2025)
• Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real‐world retrospective study from Spain and systematic review of the published data
  di: J. Cañueto, et al.
  Pubblicazione: (2024)